Semaglutide 14 mg tablet: what the evidence says about oral semaglutide doses

Why a 14 mg semaglutide tablet causes confusion, and what the MHRA actually approved

Semaglutide comes in two distinct oral forms in the UK, and they share almost nothing beyond the molecule's name. Rybelsus, the older tablet, is licensed exclusively for type 2 diabetes and comes in 3 mg, 7 mg and 14 mg strengths. Wegovy tablets, approved by the MHRA in June 2026, are licensed for weight management and carry a completely separate dose schedule: 1.5 mg, 4 mg, 9 mg, and 25 mg. These schedules do not overlap. The 14 mg tablet has no place in the weight-loss ladder at any stage.

The MHRA's approval of the oral Wegovy tablet was significant, the UK was the first country in Europe to authorise it. It reached that point on the basis of clinical evidence from the OASIS 4 trial and a rigorous regulatory review. The dosing progression was set to match the tolerability profile seen in those trials, not to mirror the Rybelsus diabetes schedule. Anyone who encounters a seller offering a 14 mg tablet described as a weight-loss treatment should treat that as a serious warning sign about the product's legitimacy. You can report suspect sellers at the MHRA's Yellow Card scheme.

If you're trying to understand how the dose schedule actually works, the oral semaglutide dose guide walks through each step and what the prescriber looks for before moving you to the next level. That context matters, because the progression is clinically led, not calendar-driven.

What the OASIS 4 trial data tells us about effective oral semaglutide doses

The MHRA based the Wegovy tablet approval on evidence from OASIS 4, a phase 3 trial involving 307 adults with obesity or overweight alongside at least one weight-related condition, none of whom had type 2 diabetes, followed over 64 weeks. Participants who took oral semaglutide lost an average of around 13.6% of body weight compared with roughly 2.4% in the placebo group. Among those who adhered fully to treatment across the whole period, the average reached approximately 16.6%, a meaningful difference that the trial authors and Novo Nordisk have been careful to frame as the adherence-dependent ceiling rather than the typical outcome.

Both figures come from the 25 mg maintenance dose, reached after a structured titration. The trial did not test a 14 mg dose as a maintenance level, nor did it identify any clinical rationale for one. The gap between 9 mg and 25 mg in the Wegovy schedule is deliberate: it reflects how absorption of the co-formulated tablet behaves at each level, and the prescriber's job is to move through those steps at a pace the patient tolerates.

Side effects in OASIS 4 were predominantly gastrointestinal. Around 74% of participants on active treatment reported at least one GI event compared with 42% on placebo, nausea, vomiting, constipation and diarrhoea were the most common. The majority were mild to moderate and eased as the body adjusted. The NHS semaglutide medicines page lists the full side-effect profile and explains when symptoms warrant medical attention.

How oral semaglutide dosing actually works, and what 14 mg gets wrong

The Wegovy tablet is taken first thing in the morning on an empty stomach, swallowed whole with no more than about 120 ml of plain water, then a wait of at least 30 minutes before food, drink or other oral medicines. The absorption mechanism depends on an enhancer called SNAC, and both the empty-stomach requirement and the water restriction exist to protect that process. Coffee, juice or a larger volume of water will reduce absorption, the timing matters more than most patients initially expect.

Because absorption is tied so tightly to the morning ritual, the dose schedule is designed around predictable tolerability at each level. Starting at 1.5 mg gives the digestive system a month to settle before the prescriber reviews progress and considers moving to 4 mg. The climb to 9 mg and eventually 25 mg follows the same pattern. A 14 mg step would sit between 9 mg and 25 mg without any trial evidence to support it as a safe or effective staging point, which is precisely why it doesn't appear in the licensed schedule.

Storage is straightforward: the tablets stay at room temperature, which makes them significantly more practical than the injection for travel and for anyone who finds refrigerator storage awkward. There's no pen to dispose of, no injection technique to learn, and the packaging that arrives via courier is plain and unbranded. One practical note, the full Wegovy tablet dosage guide covers what each step involves and what to do if you miss a morning dose. Detailed instructions on timing and any changes to the schedule belong in the Patient Information Leaflet and a conversation with your prescriber, not in a general article.

Rybelsus versus Wegovy tablets: the distinction that matters for your prescription

It's worth being direct about why this distinction matters in practice. Rybelsus 14 mg is sometimes encountered online in contexts that blur the line between diabetes management and weight loss. The medicines are not interchangeable. Using Rybelsus for weight loss would mean taking a medicine outside its licensed indication, without the clinical assessment that a weight-loss prescriber would conduct, and without the dose titration designed for the 25 mg maintenance target. The efficacy data, the monitoring protocols, and the prescribing criteria are all different.

The question of whether low-dose semaglutide tablets work for weight loss comes up regularly, and the honest answer is that only the Wegovy tablet schedule (starting at 1.5 mg) has the trial evidence and the UK licence to support weight management use. Anything outside that schedule is either a diabetes product or an unlicensed use.

For a broader look at where oral semaglutide sits alongside the injection and other options, the weight-loss treatment overview sets out the landscape clearly. Thinking about cost? The Wegovy tablet cost page explains what private treatment involves and why the prescription element is central to any legitimate price. And if you'd like to understand how the clinical team at nume approaches these decisions, our lead prescriber's profile is worth a read.

If oral semaglutide for weight management sounds right for your situation, the first step is a clinical assessment. A real prescriber reviews your answers (the same day, in working hours) and suitability is determined on the full picture, not on a single number.

Check your eligibility by starting your free consultation.